BRAIN NEOPLASMS Dotaz Zobrazit nápovědu

Despite the availability of many effective treatments, there remains a therapeutic nihilism associated with brain tumors. This highly readable second edition of 'Fast Facts: Brain Tumors' challenges this view, starting from the premise that patients with brain tumors can truly benefit from a thoughtful multidisciplinary approach.This comprehensive handbook covers all the salient features of the various brain tumors and treatment modalities in a way that will be useful to the practicing clinician.• Advances in radiology and pathology that have led to more precise and detailed diagnoses• Developments in molecular biology and imaging techniques that have improved available diagnostic modalities• New neurosurgical techniques that have enabled operations on tumors that were previously considered inoperable• Novel delivery systems that allow various treatments to reach tumors that are otherwise protected by the blood-brain barrier.This fully updated edition of 'Fast Facts: Brain Tumors' bridges the gap between primary care providers - whose role is pivotal in tumor detection and subsequent patient care - and first-level specialists such as general neurologists and neurosurgeons. Its key message is that selection of the best initial approach for an individual patient will result in the best overall outcome, both in terms of survival and quality of life.'Fast Facts: Brain Tumors' is specifically for the primary care physician whose role is pivotal in tumor detection and subsequent patient care.Contents:• Classification and epidemiology• Diagnosis• Treatment• Brain metastases• Gliomas• Meningiomas• Neuronal tumors• Pineal region tumors• Skull base tumors• Primary central nervous system lymphoma• Brain tumor syndromes and tumor-like cysts• Geriatric neuro-oncology• Useful resources

MeSH
nádory mozku MeSH
neurologie MeSH
Publikační typ
příručky MeSH

NLK Obory
neurologie
onkologie

Článek

Epilepsy associated with low-grade brain glial neoplasms

Sborník vědeckých prací lékařské fakulty Univerzity Karlovy v Hradci Králové. 1995 ; Roč. 38 (č. 4) : s. 175-183.

ISSN 0049-5514
Medvik
Zdroj

MeSH
chirurgie operační metody MeSH
dítě MeSH
dospělí MeSH
epilepsie etiologie MeSH
gliom farmakoterapie chirurgie radioterapie MeSH
lidé MeSH
nádory mozku chirurgie komplikace MeSH
svalové křeče etiologie terapie MeSH
Check Tag
dítě MeSH
dospělí MeSH
lidé MeSH
mužské pohlaví MeSH
ženské pohlaví MeSH

Článek

Flow cytometry in brain tumors. 1. ploidy abnormalities

Neoplasma. 1986 ; Roč. 33 (č. 1) : S. 49-55.

ISSN 0028-2685
Medvik
Zdroj

Článek

Ph- myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide

Arterial thrombosis is a common complication in patients with Ph- myeloproliferative neoplasms (MPN). ...

Journal of thrombosis and thrombolysis. 2021 ; 51 (1) : 112-119. [pub] -

J Thromb Thrombolysis
ISSN 1573-742X
Medvik
Zdroj

Arterial thrombosis is a common complication in patients with Ph- myeloproliferative neoplasms (MPN). We searched for the risk factors of stroke in MPN patients from anagrelide registry. We analyzed the potential risk factors triggering a stroke/TIA event in 249 MPN patients with previous stroke (n = 168) or Transient Ischemic Attack (TIA) (n = 140), and in 1,193 MPN control subjects (without clinical history of thrombosis). These patients were registered in a prospective manner, providing a follow-up period after Anagrelide treatment. The median age of the patients in the experimental group was of 56 years of age (ranging from 34-76) and of 53 years of age (ranging from 26-74) in the control group (p < 0.001). Using a multivariate model, we determined the following as risk factors: JAK2V617F mutation (OR 2.106, 1.458-3.043, p = 0.006), age (OR 1.017/year, 1.005-1,029, p = 0.006), male gender (OR 1.419, 1.057-1.903, p = 0.020), MPN diagnosis (OR for PMF 0.649, 0.446-0.944, p = 0.024), BMI (OR 0.687 for BMI > 25, 0.473-0.999, p = 0.05) and high TAG levels (OR 1.734, 1.162-2.586, p = 0.008), all of which were statistically significant for CMP development. Concerning the risk factors for thrombophilia, only the antiphospholipid syndrome (OR 1.994, 1.017-3.91, p = 0.048) was noteworthy in a stroke-relevant context. There was no significant difference between the blood count of the patients prior to a stroke event and the control group, both of which were under a cytoreductive treatment. We found that age, male gender, JAK2V617F mutation, previous venous thrombosis, and hypertriglyceridemia represent independent risk factors for the occurrence of a stroke in Ph- MPN patients.